2. Search Result
Search Result
Results for "

LPA2

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113973
    LPA2 antagonist 2

    		LPL Receptor Cancer
    LPA2 antagonist 2 (H2L 5226501) is a selective LPA2 antagonist with an IC50 of 28.3 nM and a Ki of 21.1 nM. LPA2 antagonist 2 is >480-fold more selective than LPA3 (IC50 of 13.85 μM) .
    LPA2 antagonist 2
  • HY-18075
    LPA2 antagonist 1
    4 Publications Verification

    		 LPL Receptor Cancer
    LPA2 antagonist 1 is a LPA2 antagonist with an IC50 of 17 nM.
    LPA2 antagonist 1
  • HY-114380
    Radioprotectin-1

    		LPL Receptor Others
    Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA2), with an EC50 value of 25 nM for murine LPA2 subtype .
    Radioprotectin-1
  • HY-100676
    GRI977143

    		LPL Receptor Caspase Inflammation/Immunology Cancer
    GRI977143 is a specific LPA2 receptor agonist, with an EC50 of 3.3 μM .
    GRI977143
  • HY-117779
    DBIBB
    2 Publications Verification

    		 Apoptosis Endocrinology
    DBIBB is a specific nonlipid agonist of the type 2 G protein coupled receptor for lysophosphatidic acid (LPA2). DBIBB mitigates the gastrointestinal radiation syndrome, increases intestinal crypt survival and enterocyte proliferation, and reduces apoptosis. DBIBB represents a agent candidate capable of mitigating acute radiation syndrome caused by high-dose γ-radiation to the hematopoietic and gastrointestinal system .
    DBIBB
  • HY-173324
    LPA2 antagonist 5

    		LPL Receptor Others
    LPA2 antagonist 5 (EX1) is a LPA2 antagonist, with an IC50 of 4.05 nM .
    LPA2 antagonist 5
  • HY-173325
    LPA2 antagonist 6

    		LPL Receptor Cardiovascular Disease
    LPA2 antagonist 6 (example 2) is an antagonist of Lp(a). LPA2 antagonist 6 inhibits Lp(a) formation with an IC50 value of 2.33 nM. LPA2 antagonist 6 can be used in the research of cardiovascular disease .
    LPA2 antagonist 6
  • HY-171906
    1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA

    1-Arachidonoyl-sn-glycerol 3-phosphate; 1-Arachidonoyl LPA; LPA (20:4)

    		 LPL Receptor Inflammation/Immunology
    1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA is a phospholipid containing arachidonic acid at the sn-1 position. It is a precursor to 1-arachidonoyl glycerol (1-Monoarachidin; HY-130567) . 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA binds to the LPA2/EDG4 receptor with an EC50 value of approximately 10 nM [2]. It prevents TNF-α and IL-6 secretion in wild-type but not Lpa2-/- dendritic cells stimulated by LPS . It also decreases differentiation of HT-29 human colon carcinoma cells to goblet cells in the presence of sodium butyrate .
    1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA
  • HY-171906A
    1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA sodium

    1-Arachidonoyl-sn-glycerol 3-phosphate sodium; 1-Arachidonoyl LPA sodium; LPA (20:4) sodium

    		 LPL Receptor Cancer
    1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) (1-Arachidonoyl-sn-glycerol 3-phosphate (sodium)) is a phospholipid with arachifonic acid at the sn-1 position. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) binds to the LPA2/EDG4 receptor (EC50 of 10 nM). 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can be found in rat brain as 37% of the arachidoinic acid-containing lysophosphatidic acid species. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) is the precursor to 1-arachidonoyl glycerol. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can prevent TNF-α and IL-6 secretion in wild type LPS-stimulated dendritic cells. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) reduces differentiation of HT-29 colon carcinoma cells into goblet cells when sodium butyrate is present [2] .
    1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA sodium
  • HY-118539
    NSC12404

    		LPL Receptor Others
    NSC12404 is a weak and specific LPA2 receptor agonist .
    NSC12404
  • HY-107616
    H2L5186303
    2 Publications Verification

    		 LPL Receptor Apoptosis Inflammation/Immunology
    H2L5186303 is a potent and selective LPA2 receptor antagonist with an IC50 of 9 nM. H2L5186303 promotes Apoptosis. H2L5186303 inhibits cell proliferation and motility. H2L5186303 has anti-inflammatory effects [2] .
    H2L5186303
  • HY-114379
    AS2717638
    2 Publications Verification

    		 LPL Receptor Neurological Disease Inflammation/Immunology
    AS2717638 is a highly selective, brain-penetrant and orally active lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC50 value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases [2].
    AS2717638
  • HY-RS07749
    LPAR2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    LPAR2 Human Pre-designed siRNA Set A contains three designed siRNAs for LPAR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LPAR2 Human Pre-designed siRNA Set A
    LPAR2 Human Pre-designed siRNA Set A
  • HY-RS07750
    Lpar2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Lpar2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lpar2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Lpar2 Mouse Pre-designed siRNA Set A
    Lpar2 Mouse Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: